Confusion reigns over InterOil's Papua New Guinea sale, shares -16.5% • 8:18 AM
•InterOil (IOC) is halted after falling 21% premarket on news of the sale of a 61.3% stake in its Papua New Guinea gas fields to Total (TOT) for as much as $3.6B, as the clarity of the deal is questioned.
•The press release issued by IOC reads little like the one issued by TOT: Total says depending on the results of the delineation of the Elk and Antelope gas fields, "this could lead to a final investment decision by 2016 for the development of the fields and the construction of a liquefaction plant located onshore on the Gulf of Papua."
Now if VGX-3100 trial is validated obviously then the entire pipeline for INO is the sky's limit. From a scientific view if immunotherapy is not the answer to cancer treatment or other medical issues I don't see another option available for a cure. Because chemicals I believe will be consider barbaric antiquated medical therapy in the future and stimulation of ones immune system is the key to most if not all underlining diseases processes.
There are too many things to mention that is working in the background, think of them. Any one of the multiple things can drive this stock alone. All we need is one of the many projects to come to fruition and we reap the rewards..
Camtek Ltd. (NASDAQ and TASE: CAMT) ('The Company') today announced that in light of the high trading volume of the Company's shares and rumors that have been circulating in the media over the course of the past few days, it wishes to clarify that, as reported previously, it is now in the advanced stages of the development of the GreenJet, a digital 3D printing system used for the deposition of solder mask designated for the printed circuit board industry (the "GreenJet System"). The first installation of the GreenJet System for evaluation in a customer's manufacturing environment is expected to take place in the beginning of 2014 and, subject to the results, the Company expects the first commercial sales of the GreenJet System to take place during 2014.
In addition, the Company wishes to inform that it has decided to focus on its two primary markets (products for the printed circuit board industry and inspection products for the semi-conductor market), and will not continue with development of future models of its Xact product line designed for the sample preparation of models for the characterization and failure analysis in the semi-conductor industry. The Company will continue to sell and support the existing Xact products.
Therefore, as a future growth engine, in addition to the existing products lines, the Company will focus its activity in the field of digital 3D printing for the printed circuit board industry, including the GreenJet System.
...............................................................................I cleaned my oilburner!....G.
up it and read..
Unlike other biologic vaccines, the company’s vaccines are made up of synthetic-DNA computer generated strands that are mixed with water. This helps in giving Inovio Pharmaceuticals Inc (NYSEMKT:INO) product candidates a big lead. This is because the synthetic therapies do not run any risk of producing viruses that they are aiming to treat. Thus it is possible to manufacture them very easily and they can also be stored effectively at room temperature.
Large number of patents
These vaccines are synthetic. This has helped the company build a vast patent and IP portfolio for all its products. At the moment, Inovio’s pipeline has more than 400 patents and there are no signs that it will slow its IP expansion in any way. The one thing that the company has been patenting very aggressively so far is the coded DNA-sequences.
These are the foundational-mechanism of action for its therapies and vaccines. Via these synthesized DNA-transcription codes, the company’s vaccines operate in activating the targeted immunological responses that trigger the patient’s immune systems and help them fight disease more effectively.